Stay updated on Pembrolizumab & Blinatumomab in ALL Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab & Blinatumomab in ALL Clinical Trial page.

Latest updates to the Pembrolizumab & Blinatumomab in ALL Clinical Trial page
- ChecktodayNo Change Detected
- Check7 days agoNo Change Detected
- Check15 days agoChange DetectedAdded a Locations section showing the California site and updated the page revision from v3.3.2 to v3.3.3. Removed the HHS Vulnerability Disclosure and the California Locations entry.SummaryDifference0.2%

- Check22 days agoNo Change Detected
- Check36 days agoChange DetectedRevision: v3.3.2 is shown on the page, and Revision: v3.3.1 has been removed.SummaryDifference0.1%

- Check44 days agoChange DetectedRevision: v3.3.1 was added replacing v3.2.0, a minor site version update with no changes to study content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check51 days agoChange DetectedThe government funding operating-status notice at the top was removed. Study details and navigation remain unchanged.SummaryDifference0.4%

- Check65 days agoChange DetectedAdministrative updates were made to the study record, including last update dates and QC criteria; no changes to the study design, eligibility criteria, primary or secondary outcomes, or enrollment. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check94 days agoChange DetectedSummary: The page adds a government-operating-status notice and a v3.2.0 release tag, while removing the v3.1.0 tag. The new notice is the significant change, signaling updated operating status and potential transaction delays.SummaryDifference3%

Stay in the know with updates to Pembrolizumab & Blinatumomab in ALL Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab & Blinatumomab in ALL Clinical Trial page.